The massive Australian ecosystem.

Australia is an ideal location for early pharmaceutical development, streamlining development as a world leader in research and healthcare and a go-to location for clinical trials.

 

Australia has nine top-100-ranked universities and academic institutes, a highly skilled and knowledgeable workforce with 7,000 PhD graduates annually, subsidised healthcare, and attractive grants and incentives for pharmaceutical giants to day-one start-ups.

 

Australian-based developers are globally advantaged. The Australian regulator, the TGA, is globally recognised and comparable with key jurisdictions, the U.S. FDA and European EMEA, accepting data from pre-clinical and clinical research conducted in Australia.

 

Australia is a receptive proving ground for new medicines and a stable democratic economy on the doorstep of Asian markets with a reputation for quality exports.

 

Australia is an ideal market for precision medicine, ATMPs, and biotechnology, with regulatory facilities for research and manufacturing of both small molecules and biological subsectors, including gene, cell, antibodies, and RNA therapies. 

​

Australia is where little things grow!